Status:
UNKNOWN
Danish Hypertension Prevention Project - DHYPP
Lead Sponsor:
Karin Skov
Collaborating Sponsors:
University of Aarhus
AstraZeneca
Conditions:
Hypertension
Eligibility:
All Genders
18-36 years
Phase:
PHASE3
Brief Summary
The present study examine healthy, normotensive subjects 18 to 36 years of age whose both parents have essential hypertension. The subjects receive treatment with either the AT1-antagonist candesartan...
Detailed Description
Essential hypertension, a major health problem worldwide, is a disease generally considered to require life-long treatment. However, evidence suggests that hypertension is caused by specific phenotypi...
Eligibility Criteria
Inclusion
- Both parents have essential hypertension
- Age 18 - 36 years
- Caucasians
- Diastolic blood pressure less than 85 mmHg at inclusion time
- Female participants using orale anticonceptives ot intrauterine devices
Exclusion
- Clinical or biochemically signs of disease in kidney, liver, or endocrine organs
- Diastolic blood pressure above 85 mmHg at inclusion time
- Pregnancy or pregnancy wish
- Daily medication, except for orale anticoncetives -
Key Trial Info
Start Date :
November 1 2000
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2014
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00150631
Start Date
November 1 2000
End Date
December 1 2014
Last Update
November 26 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Karin Skov
Aarhus, Denmark, 8000